Acute Stroke Care: Rapid Unblocking Of Vessels, Mending Ruptures, And Recovery
Funder
National Health and Medical Research Council
Funding Amount
$204,399.00
Summary
During this fellowship, A/Prof Meretoja will 1) use blood biomarkers, telemedicine, and ambulance-based imaging to streamline the time-critical therapy of stroke thrombolysis, 2) run a pharmaceutical trial of the drug tranexamic acid in intracerebral haemorrhage, and 3) use stroke registries in Australia and Finland to disseminate best practices in stroke care pathways.
Enhanced Control Of Hypertension And Thrombolysis In Stroke Study (STAY ENCHANTED)
Funder
National Health and Medical Research Council
Funding Amount
$2,437,384.00
Summary
"Clot busting" treatment is the only approved medical treatment for the commonest type of stroke, ischaemic stroke. However, uptake of treatment remains poor, mainly due to the known major risk of bleeding in the brain. STAY ENCHANTED is an international clinical trial to investigate whether "clot-busting" can be made safer using a lower dose and/or immediate blood pressure lowering. A safer more effective regime could have a major global health impact.
Patterns Of Care And Outcomes For Subarachnoid Haemorrhage: A Data Linkage Study
Funder
National Health and Medical Research Council
Funding Amount
$125,625.00
Summary
As many as 30% of people with subarachnoid haemorrahge (SAH) die within 90 days. Survivors are often left disabled. Death rates appear to be decreasing. Identifying health service variables that impact positively on survival has the potential to inform health policy and practice. We will describe variations in mortality, hospital re-admission and patterns of care. The study will observe the uptake of new SAH management including new neurosurgical techniques.
This Australian-led, investigator initiated and conducted study, is the first and only large scale clinical trial designed to assess the balance of potential benefits and risks of early rapid blood pressure lowering in intracerebral haemorrhage stroke, a disease in which there is still no convincing evidence of benefit from any medical treatment, where the role of surgery remains controversial, and from which the chances of surviving has failed to improve in recent decades.
Evaluation Of Combined Mild Hypothermia And Magnesium As A Neuroprotective Therapy Following Cerebral Ischaemia/stroke
Funder
National Health and Medical Research Council
Funding Amount
$310,286.00
Summary
Stroke-cerebral ischaemia affects over 50,000 Australians every year and is Australia's leading single cause of disability and third greatest cause of death after heart disease. About 25% of people who suffer a stroke die within one month while most survivors are disabled because of impaired speech, memory, thought processes, vision, balance, or motor control of the limbs (paralysis). The direct and indirect cost of stroke-cerebral ischaemia to the Australian community is over $2 billion annuall ....Stroke-cerebral ischaemia affects over 50,000 Australians every year and is Australia's leading single cause of disability and third greatest cause of death after heart disease. About 25% of people who suffer a stroke die within one month while most survivors are disabled because of impaired speech, memory, thought processes, vision, balance, or motor control of the limbs (paralysis). The direct and indirect cost of stroke-cerebral ischaemia to the Australian community is over $2 billion annually. The ability to inhibit or limit brain damage once a stroke has occurred will reduce the devastating effects of stroke to patients and the Australian community. Despite decades of research, there is no totally satisfactory drug that directly inhibits brain damage following stroke; the search for new treatments is paramount. A stroke occurs when there is a reduced blood supply to the entire brain (global cerebral ischaemia; eg. cardiac arrest, closed head injury) or to a specific region of the brain, usually as a result of a blockage in a brain artery (focal cerebral ischaemia or thrombo-embolic stroke). This project will evaluate the efficacy of combined magnesium and mild hypothermia (35) treatment protocols to reduce brain damage in animal models of focal and global cerebral ischaemia. This work stems from our recent data showing for the first time that magnesium is only neuroprotective in animals following cerebral ischaemia when present with hypothermia. Thus our data indicates that magnesium, when combined with hypothermia is an effective stroke therapy. Moreover treatment with magnesium-mild hypothermia has several attractions. Both are likely to have multiple mechanisms of action, are cheap to administer and safe. Importantly, the experimental findings from this project will enable better design of future clinical trials to test the efficacy of combined magnesium-modest hypothermia to improve patient outcome following stroke.Read moreRead less